COMMUNIQUÉS West-GlobeNewswire

Key CareDx Events Scheduled at American Transplant Congress 2018
01/06/2018
CareDx will have a strong presence at ATC, all major US transplant centers will be in attendance BRISBANE, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on [...]
CLS Holdings USA Comments on Application Process for Additional Nevada Dispensaries
01/06/2018
LAS VEGAS, June 01, 2018 (GLOBE NEWSWIRE) -- (OTCQB:CLSH) CLS Holdings USA, Inc. “CLS,” a development stage diversified Cannabis Company operating as Cannabis Life Sciences, today announced Oasis Cannabis plans to apply [...]
Oryzon to present at upcoming international conferences
01/06/2018
BIO International Convention 2018, Boston, Ma, USA Jefferies 2018 Global Healthcare Conference, New York, USA 14 th Spring European Midcap Event, Paris, France MADRID, Spain and CAMBRIDGE, Mass., June 01, 2018 (GLOBE [...]
PPD and NeoGenomics Forming Global Strategic Alliance for Pathology and Molecular Testing Solutions
01/06/2018
Expanding global oncology testing for clinical trials WILMINGTON, N.C., June 01, 2018 (GLOBE NEWSWIRE) -- Pharmaceutical Product Development, LLC ( PPD ), a leading global contract research organization (CRO), and [...]
MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
01/06/2018
Europe represents potentially the largest market for metreleptin with expected authorization in both generalized and partial lipodystrophy VANCOUVER, British Columbia, June 01, 2018 (GLOBE NEWSWIRE) -- Novelion [...]
Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
01/06/2018
Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology Positive CHMP opinion based on comprehensive [...]
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
01/06/2018
If approved, Aimovig ® (erenumab) is expected to be the first and only available therapy designed specifically for migraine prevention in the EU Positive opinion based on robust data package demonstrating Aimovig's [...]
Oncolytics Biotech® Announces Listing on Nasdaq Capital Market
01/06/2018
CALGARY, Alberta and SAN DIEGO, June 01, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN ® (pelareorep), an intravenously delivered immuno-oncolytic virus [...]
Epizyme to Host Investor Conference Call to Discuss Interim Follicular Lymphoma Clinical Data
01/06/2018
CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a conference call at 8:30 a.m. [...]
CytomX Announces Conference Call and Webcast to Review PROCLAIM-072 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
01/06/2018
SOUTH SAN FRANCISCO, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody [...]
TG Therapeutics, Inc. Recaps Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association
01/06/2018
NEW YORK, June 01, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today recapped the schedule of data presentations at the upcoming 54 th Annual Meeting of the American Society of Clinical Oncology (ASCO [...]
Myriad Genetics Presents Second Pivotal Validation Study for riskScore™ Test at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
01/06/2018
riskScore Provides Women Who Test Negative for Hereditary Breast Cancer Mutations Definitive Information about their 5-Year and Lifetime Risk of Breast Cancer SALT LAKE CITY, June 01, 2018 (GLOBE NEWSWIRE) -- Myriad [...]
MPI - Clinical data on PARP inhibitor 2X-121 and DRP response prediction validation to be presented on the world's largest cancer congress ASCO 2018
01/06/2018
Hoersholm, Denmark, June 1, 2018 - Medical Prognosis Institute A/S ("MPI") hereby announces that clinical data on PARP inhibitor 2X-121 and DRP response prediction validation is to be presented on the world's largest [...]
ObsEva SA to Seek SIX Share Listing
01/06/2018
Geneva, Switzerland and Boston, MA -June 1, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that [...]
Summit Therapeutics plc : Notice of 1st Quarter Results
01/06/2018
Summit Therapeutics plc ("Summit", or the "Company") Summit Therapeutics Provides Notice of Financial Results for the First Quarter Ended 30 April 2018 Oxford, UK, and Cambridge, MA, US, 1 June 2018 - Summit [...]
Shire plc : Total voting rights
01/06/2018
Total Voting Rights June 1, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority's (the "FCA") Disclosure Guidance and Transparency Rules, notifies the [...]
As Anticipated, Sarepta Receives Negative CHMP Opinion for EXONDYS® (eteplirsen) to Treat Patients with Duchenne Muscular Dystrophy in Europe
01/06/2018
-- Sarepta will seek re-examination of the opinion and request that a Scientific Advisory Group (SAG) be convened -- CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a [...]
Summit Therapeutics Provides Notice of Financial Results for the First Quarter Ended 30 April 2018
01/06/2018
OXFORD, United Kingdom and CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT) will announce its financial results for the first quarter ended 30 April 2018 on 5 June [...]
BeiGene to Present Data on Zanubrutinib and Host an Investor Call from the 23rd Congress of the European Hematology Association
01/06/2018
BEIJING, China and CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted [...]

Pages